The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | Exploring treatment characteristics of patients with hereditary transthyretin amyloidosis
Chafic Karam, MD, University of Pennsylvania, Philadelphia, PA, discusses a recent publication on the treatment characteristics of patients with hereditary transthyretin (ATTR) amyloidosis. The study examines FDA approved agents such as tafamidis, patisiran, inotersen, and vutrisiran, for cardiac and neuropathic amyloidosis. The complexities of treating patients with mixed phenotypes and the safety and efficacy of combination therapies are highlighted. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
